ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication-Reference-Cited by-同舟云学术

ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication

Published:2016-09-06 Issue:43 Volume:7 Page:70323-70335
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Koo Seong Joo¹,Fernández-Montalván Amaury E.¹,Badock Volker¹,Ott Christopher J.²³⁴,Holton Simon J.¹,von Ahsen Oliver¹,Toedling Joern¹,Vittori Sarah²³,Bradner James E.²³⁴⁵,Gorjánácz Mátyás¹

Affiliation:

1. Drug Discovery, Bayer Pharma AG, Berlin, Germany

2. Center for the Science of Therapeutics, Broad Institute, Cambridge, MA, USA

3. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

4. Department of Medicine, Harvard Medical School, Boston, MA, USA

5. Present address: Novartis Institute for BioMedical Research, Cambridge, MA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PDGF-BB overexpression in p53 null oligodendrocyte progenitors increases H3K27me3 and induces transcriptional changes which favor proliferation;Neoplasia;2024-11

2. PDGF-BB overexpression in p53 null oligodendrocyte progenitors increases H3K27me3 and induces transcriptional changes which favor proliferation;2024-05-14

3. Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains;Journal of Medicinal Chemistry;2024-05-11

4. Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells;Cancers;2024-04-29

5. Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer;Molecular Therapy: Oncology;2024-03